InvestRight
Currency
Theme
$1 = ₹95.71 as of 23 Aug
LRCX $269.61 -7.3% MU $924.39 +6.6% DIXON.NS ₹14,507.00 +6.3% SPCX $121.61 +5.7% BLK $1,126.63 +3.5% ORCL $146.47 +3.4% CNL $14.68 +3.0% CVX $193.18 -2.7% PARAS.NS ₹1,377.50 +2.6% ADANIENT.NS ₹3,157.30 +2.6%

LIFE INSURA CORP OF INDIA

LICI.NS NSE

There isn't enough cash-flow history to value Life Insura Corp Of India yet. Its growth outlook scores strong; the balance sheet is solid.

$4.43 -0.71% today as of 29 Jul, 7:27 PM
Insurance - Life

At a glance

tap a tile to dig in

Otto's verdict

the tiles above, in a line each

Not investment advice — Otto just crunches numbers.

Price trend

-3.9% over one year · NIFTY 50 -3.2%

2025-08-20 · $4.59 2026-08-21 · $4.41

What think

The market's move: -3.9% over the past year

52-wk low $3.77 high $4.89

Trading 59% up its 52-week range. Price is the market's live vote — not advice.

The snowflake

checks passed on each axis
Value n/a Future 75% Past 100% Health 100% Dividend 67%
  • Value 0/— checks
  • Future 3/4 checks
  • Past 4/4 checks
  • Health 2/2 checks
  • Dividend 2/3 checks
What does this show?

Five quick health scores — Value, Future, Past, Health and Dividend — each 0–100%. A bigger, more even shape means a stock that scores well across the board; a spiky one is strong on some axes and weak on others.

Learn more on Investopedia →

Fair value

our estimate · not analyst forecast

Not enough cash-flow history to estimate a fair value for LICI.NS yet.

What does this show?

Our estimate of what one share is worth based on the cash the business is expected to generate (a discounted-cash-flow model), next to today's price. Below fair value hints undervalued, above hints expensive — it's an estimate, not a guarantee.

Learn more on Investopedia →

Health checks

13 checks run on free data
Show all 13 checks by axis

Value 0/— passed

  • Trading below our fair-value estimate
  • P/B below industry industry P/B not on the free feed
  • P/E below industry industry P/E not on the free feed
  • P/E below peer average peer P/Es land after the next refresh
  • P/S sane vs its own history needs multi-year P/S (Tier B)
  • More than 20% below fair value

Future 3/4 passed

  • Earnings trending up 16.9%/yr over 3yr
  • Growth beats the industry industry growth not on the free feed
  • Earnings growth beats the market 16.9%/yr vs market ~9.0%
  • Revenue trending up 7.3%/yr over 3yr
  • Return on equity improving ROE 32.5% vs 77.9% 3yr ago

Past 4/4 passed

  • Earnings grew over the period 360.0B → 574.5B
  • High-quality earnings (few one-offs) one-off detection deferred — needs statement detail
  • Growth accelerating vs its average latest 18.9%/yr vs 16.9% average
  • Revenue higher than five years ago 7.9T → 9.7T
  • Return on equity above 20% ROE 40.8%

Health 2/2 passed

  • Debt/equity falling over time n/a
  • Debt is under 40% of equity debt/equity 0%
  • Debt well covered by cash flow
  • Interest comfortably covered by profit EBIT covers interest 432.5×
  • Short-term assets cover long-term debt n/a
  • Short-term assets cover short-term bills n/a

Dividend 2/3 passed

  • Dividend covered by earnings and cash flow n/a
  • Dividend growing over time n/a
  • No dividend cut in recent years n/a
  • Payout ratio under 75% payout 13.2% of earnings
  • Yield beats the market yield 2.36% vs market ~1.5%
  • Yield in the top quartile of payers yield 2.36% vs 2.68% cut among the 60 payers Otto tracks
What does this show?

Pass/fail rules on the company's finances — debt levels, profitability, cash cover and so on. More greens means a sturdier balance sheet; an n/a just means we didn't have that data point.

Learn more on Investopedia →

Past performance

recent history from Yahoo Finance

Revenue

2023 · 82.0B 2026 · 101.2B

Earnings

2023 · 3.8B 2026 · 6.0B

Free cash flow

2023 · 5.6B 2026 · -2.9B

dashed line = what it'd look like growing at our ~9% market-average benchmark, for comparison

Deeper 10-yr statements are US-only for now — Otto's showing LICI.NS's Yahoo figures instead.

What does this show?

How revenue, earnings and free cash flow have grown over the years. Bars rising left-to-right show a growing business; the dashed line is a market-average pace for comparison.

Learn more on Investopedia →

Future

trend, not analyst forecast

Revenue · extended at 7.3%/yr

2023 · 82.0B 2029 · 124.9B projected

Earnings · extended at 15.0%/yr

2023 · 3.8B 2029 · 9.1B projected

Dashed bars just extend the historical trend (capped at ±15%/yr) — the same growth our DCF uses. It's arithmetic on the past, not an analyst forecast; real futures bend.

What does this show?

Solid bars are history; dashed bars simply extend the past growth trend a few years forward — capped so it stays sane. It's a trend line, not an analyst forecast.

Learn more on Investopedia →

Dividend

from cash actually paid, not promises
2.36% current yield · market ~1.5%
0 yrs without a cut, on record
over the saved record
What does this show?

The share of profit paid back to shareholders as cash. Yield is that cash as a % of the price; the payout gauge shows how much of earnings is paid out (over ~75% can be hard to sustain).

Learn more on Investopedia →

Ownership & insiders

Insider-trade filings come from SEC EDGAR, which covers US companies only — there's no free equivalent for Indian filings yet, so Otto skips this one for LICI.NS.

What does this show?

Buys and sells by the company's own directors and officers, from their SEC filings. Insiders sell for many reasons, but clusters of open-market buying can signal confidence.

Learn more on Investopedia →

Competitors

Insurance - Life · tap to jump

No competitors listed for LICI.NS yet — sign in to add the first one.

What does this show?

A few peers in the same business, each with its own mini snowflake, so you can see how this company stacks up rather than judging it in isolation. Anyone signed in can add a missing competitor — it shows for everyone, marked as user-added.

Learn more on Investopedia →

In the news

My notes